Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;12:1046143. doi: 10.3389/fonc.2022.1046143

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Tian, Yi, Feng, Chu, Liu, Zhang, Zhang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Western blot analysis of PI3K and Akt in cells treated with LY294002 and SC-79. (A) Western blot images. The left column shows protein names, including p-PI3K, PI3K, p-Akt, Akt, and β-actin, which was used as loading control. The top row shows two cell lines HCT116 and LoVo, and drug treatment with different combinations. ‘LY’ represents LY294002. (B) Bar plots of densitometric analysis. Protein expression levels are normalized to that of the loading control. Columns show the mean ± S.D. One-way ANOVA was used to analyze P values between groups. All groups are compared with the ‘Control’ group, the ‘CTX’ group is compared with the ‘CTX+LY’ or ‘CTX+PD+SC79’ group. *P < 0.05 represents a significant difference. (C) The signaling pathway by which PD enhances the cytotoxicity of CTX. A PI3K inhibitor and an Akt activator were used to confirm the inhibitory effect of PD on PI3K.